Background

Plasminogen Activator Inhibitor-1 (PAI-1) is a glycoprotein and member of the serine protease inhibitor (serpin) superfamily. PAI-1 is the primary inhibitor of tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This inhibition exhibits antiproteolytic properties that can lead to myocardial infarction and thromboembolic disease with elevated levels of PAI-1. Additionally, PAI-1 is thought to play a role in the function of tissue remodeling and tumor metastasis.

Assay Principle

This is an ELISA for the quantitative analysis of PAI-1 levels in biological fluid. This test kit operates on the basis of sandwich ELISA where all PAI-1 forms (complexed, latent and active) are captured and quantitated with the use of an HRP labeled secondary antibody.

The free, latent, and complexed PAI-1 all bind to the PAI-1 capture antibody coated on the well of the microtiter plate. Next, a PAI-1 primary antibody is added to bind to the captured PAI-1 on the microtiter plate. An HRP conjugated secondary antibody is then added for detection of the total PAI-1. Optimal color is reached at 10 minutes when read at 450 nm. Quantitative test results are obtained by the measure and comparison of the sample and standard absorbance readings.